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Abstract 
Background Current treatments of chronic hepatitis C virus (HCV) are effective, but expensive and susceptible 
to induce significant side effects. 
Objectives To evaluate the proportion of HCV patients who are eligible for a treatment. 
Methods In a database comprising 1726 viraemic HCV patients, the files of 299 patients who presented to the 
same hepatologist for an initial appointment between 1996 and 2003 were reviewed. 
Results Patients' characteristics were age 43.1 ± 15.6 years, 53% male and 92% Caucasian. The main risk factors 
were transfusion (43%) and drug use (22%). Genotypes were mostly genotype 1 (66%), genotype 3 (12%) and 
genotype 2 (10%). These characteristics were not different from those of the whole series of 1726 patients. A 
total of 176 patients (59%) were not treated, the reasons for non-treatment being medical contraindications 
(34%), non-compliance (25%) and normal transaminases (24%). In addition, 17% of patients declined therapy 
despite being considered as eligible, mainly due to fear of adverse events. Medical contraindications were 
psychiatric (27%), age (22%), end-stage liver disease (15%), willingness for pregnancy (13%), cardiac 
contraindication (7%) and others (16%). Only 123 patients (41%) were treated. A sustained viral response was 
observed in 41%. The treatment was interrupted in 16% for adverse events. 
Conclusions The majority of HCV patients are not eligible for treatment. This implies that, with current 
therapies, only 17% of patients referred for chronic HCV become sustained responders. Some modifications of 
guidelines could extend the rate of treatment (patients with normal transaminases), but an important barrier 
remains the patients' and the doctors' fear of adverse events.  
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Introduction 
Hepatitis C virus (HCV) is an important cause of chronic liver disease worldwide with a significant global 
mortality and morbidity. The World Health Organization estimates that about 3% of the world population is 
currently infected with HCV. In the United States, the estimated prevalence is 1.8% [1]. In Europe, among blood 
donors, the prevalence of HCV ranged from very low (< 0.1%) in the United Kingdom and Scandinavia, to low 
(0.1-0.5%) in the rest of Western Europe and moderate (0.6%) in Southern Europe [2]. In a sample of the general 
population in Belgium, the seroprevalence was 0.87% [3]. More than 70% of newly infected patients progress to 
chronic infection with its attendant complications of cirrhosis, liver failure and hepatocellular carcinoma. 
Furthermore, the health-related  quality of life is  significantly compromised in persons with chronic HCV 
compared with the general population [4]. At present, the management of patients with hepatitis C largely 
focuses on combination antiviral treatment using a 24-week or 48-week course of peginterferon and ribavirin [5]. 
These therapies proved to be effective. They are susceptible, however, to inducing significant adverse effects. In 
addition, they are expensive, and entail a substantial socioeconomic burden. It has been shown that the therapy 
was cost-effective, in particular, in US [6], Spanish [7], German [8] and Belgian settings [9-11]. Beyond the 
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problem of the cost-effectiveness ratio, however, the global cost estimation of a treatment for a country depends 
on the number of patients actually treated per year. There is a huge discrepancy between the number of patients 
that could be potentially treated in regards of the disease prevalence and the number of patients that are actually 
treated. For Belgium, for example, only around 1000 patients are treated every year for an estimated population 
of about 90 000 infected persons. It has been suggested that a large number of patients are still unaware of their 
seropositivity. Furthermore, under-reporting by healthcare professionals is common, and many high-risk 
individuals do not have easy access to health care. Another explanation is that only a small proportion of patients 
that are seeking medical care are eventually treated. In the United States, it has been shown in the Veterans' 
population infected with HCV that 30% only of referred patients were considered eligible for therapy [12,13]. In 
this population, the most common contraindication was psychosocial factors [12]. Although the findings in 
HCV-infected US Veterans may not be directly applicable to other HCV populations (because they are more 
likely than HCV-infected US non-Veterans to have a history of alcoholism, active substance abuse, post-
traumatic stress disorder and antidepressant therapy [14]), a few studies in the general population in the United 
States also reported that many patients were not eligible for therapy [15-17]. To date, such figures are not 
available for Europe. We therefore investigated the overall antiviral treatment rate and the reasons for non-
treatment in a population of HCV-infected patients in Belgium. 
Methods 
From 1992 to 2003, the Centre for Molecular Diagnosis of Liège, Belgium has depicted 1726 viraemic HCV 
patients (i.e. those found positive for HCV-RNA by polymerase chain reaction) [18]. From that database, we 
reviewed the charts of patients who presented to the Academic Hospital Sart Tilman, Liège, Belgium, between 
1996 and 2003, for an initial appointment with the same hepatologist. The year 1996 was chosen because 
effective therapies combining interferon and ribavirin became available at that time in this hospital. Only patients 
for whom the polymerase chain reaction was requested by this hepatologist were taken into account in the 
analysis. This attitude was taken to reduce the potential bias of an over-assessment of the treatment rate due to a 
referring of patients initially evaluated in another centre and sent to the academic hospital in order to initiate the 
therapy. All patients were evaluated by the same hepatologist, who decided to treat or not to treat on the basis of 
classical guidelines. For all patients, the following information was gathered: demographics, medical history, 
modes of contamination and viral genotype. For treated patients, the rate of sustained viral response, of relapse 
after the end of therapy or of non-response was assessed, as well as the rate of premature discontinuation of 
therapy. For each untreated patient, we documented reasons for not initiating therapy such as medical 
contraindications, mood disorders, current pregnancy or desire of pregnancy, refusal, non-adherence to medical 
evaluation (defined as missing two or more clinic appointments or not attending the appointment for liver 
biopsy) and normal alanine aminotransferase (ALT) levels. 
This study was approved by the Ethics Committee of the University of Liège, Belgium. 
Statistical analysis 
Comparisons were analysed by either the chi-square test or the Student's t-test. The statistical results were 
considered to be significant at the level of 5%. 
Results 
The files of 299 patients were reviewed. The mean age was 43.1 ± 15.6 years; 157 patients (53%) were male. 
Most patients (274 patients) were Caucasians (92%), 22 patients (7%) were Africans and three patients (1%) 
were Asians. 
Risk factors for HCV acquisition were transfusion before 1992 for 127 patients (43%), intravenous drug use for 
66 patients (22%), needle-stick injury for four patients (1%), sexual for three patients (1%) and of unknown 
origin for 102 patients (33%). 
Genotypes were determined in 134 patients. Genotype 1 was the most common (89 patients, 66%). Genotype 2 
was found in 13 patients (10%), genotype 3 in 16 patients (12%), genotype 4 in 13 patients (10%) and genotype 
5 in three patients (2%). 
The characteristics of these 299 patients did not differ from those of the 1726 patients of the whole series as far 
as gender, age, proportion of genotype 1 versus non-genotype 1 and proportion of transfused patients versus non-
transfused patients were considered. Actually, 176 patients (59%) were not treated (Table 1). 
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The reasons for not fulfilling therapy criteria were: normal ALT levels (n = 43, 24%), non-adherence to 
evaluation procedures (n = 44, 25%) and medical contraindications (n = 60, 34%). The medical contraindications 
were: psychiatric (n = 16, 27%), age (n = 13, 22%), end-stage liver disease (n = 9, 15%), willingness of 
pregnancy (n = 8, 13%), significant coronary artery disease (n = 4, 7%), neoplasm other than hepatocellular 
carcinoma (n = 4, 7%), haematological disturbances (n = 3, 5%), autoimmune disease (n = 2, 3%) and 
retinopathy (n = 1, 1%). The psychiatric factors included: alcohol abuse (n = 4), current or recent drug abuse (n = 
6), current or recent depressive symptoms (n = 4) and other psychiatric disorders (n = 4) including bipolar 
disorder or schizophrenia. The median age of patients excluded from therapy due to their age was 71 years (64-
82 years). These patients were considered too old to be treated on a case-by-case decision. 
Table 1: Follow-up of 299 patients evaluated for the treatment of chronic hepatitis C 
Treated (n = 123, 41%) Untreated (n = 176, 59%) 
Sustained response, n = 50 (41%) Medical contraindication, n = 60 (34%) 
Non-response, n = 48 (39%) Non-adherence, n = 44 (25%) 
Relapse, n = 5 (4%) Normal alanine aminotransferase level, n = 43 (24%) 
Stop treatment, n = 20 (16%) Patient choice, n = 29 (17%) 
 
Table 2: Comparison between treated patients and patients eligible for therapy but who refused to be treated 
 Patients who refused 
to be treated 
Treated patients P 
n 29 123  
Male/female 12/17 71/52 NS 
Age (years) (mean±SD) 47± 13.6 41 ± 14.1 0.026 
Risk factor    
Transfusion 12 52  
Intravenous drug use 6 20 NS 
Unknown 11 42  
Genotype    
Genotype 1 14 48 NS 
Non-genotype 1 6 25  
Metavir score    
Score 0-2 16 74  
Score 3-4 3 31 NS 
There was no significant difference between treated patients and patients who refused to be treated except for age. 
 
Despite being considered eligible for treatment, 17% (n = 29) of patients declined therapy. Personal 
circumstances (e.g. currently in school, in search of a new job, living most of the time abroad) were the reasons 
to delay treatment in a few patients (n = 3). In most cases (n = 26), however, the patient's decision to delay 
therapy was the fear of adverse events. These 26 patients, theoretically eligible but who refused therapy, did not 
differ from the 123 patients who accepted therapy as far as gender, risk factors for HCV acquisition, genotype or 
stage of fibrosis were considered (Table 2). They were, however, slightly older (47 ± 13 versus 41 ± 14 years, P 
= 0.026) than patients who accepted therapy. Although most refusals could not be considered a priori as 
definitive, no patient who initially refused to be treated changed his or her mind even after some years of follow-
up and despite the improvement in the efficacy of therapies. 
Eventually, only 123 patients (41%) were treated. The treatment regimens documented during the 7-year period 
included interferon and ribavirin or pegylated interferon and ribavirin. A sustained viral response was obtained in 
41% of patients. The treatment was interrupted in 16% because of side effects. 
Discussion 
Combination therapy of peginterferon alfa-2a or alfa-2b together with ribavirin has significantly advanced the 
treatment of chronic hepatitis C and represents the current standard of care. Several large randomized clinical 
trials have demonstrated that the majority of patients achieve a sustained viral response with this combination 
therapy [19-21]. However, it appears that in the United States only a small proportion of infected patients benefit 
from these therapies. Rowan et al. [13] in a series of 580 Veterans, and Muir and Provenzale [12] in a series of 
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100 Veterans, showed that 70% and 68%, respectively, of their HCV patients had not been considered as eligible 
for therapy. Rocca et al. [17] retrospectively reviewed a series of 366 HCV patients listed in the Olmsted County 
Hepatitis C registry. For these patients, a discussion on treatment was performed for only 234 patients (64%). 
Among them, 179 (77%) remained finally untreated. In a series of 293 viraemic patients attending a teaching 
county hospital, Falck-Ytter et al. [15] showed that the rate of non-treatment was 72%. The populations of these 
series, however, were particular, with high proportions of African-Americans (24-51%) and intravenous drug 
users (43-74%) (Table 3). It was postulated that these American series could not be compared with the 
population of patients seen in Europe. Epidemiological characteristics and risk factors in our series of patients 
attending a Belgian academic hospital effectively differed from those of the American series, while being very 
close to those observed in France in a cohort of 1872 patients [22] (Table 3). Although there were statistically 
less drug users in our series than in this latter series, the distribution of risk factors in our series did not differ 
significantly from that described in another French cohort of 6664 patients [23]: 37% of transfusion-related 
transmission (versus 43% in our series) and 25% of drug addicts (versus 22%). 
We found that most (59%) patients evaluated for a treatment were actually not treated. Although we treated 
significantly more patients than in the aforementioned American series (Table 3) (probably in relation to the 
academic nature of our hospital [16] and also to the difference in patients' characteristics), a majority of patients 
were considered non-eligible for therapy. 
The most frequent reasons for not treating were medical contraindications, normal transaminases or refusal of 
therapy by the patient. Among motives for not initiating a treatment, 34/176 (19%) were definitive (end-stage 
liver disease, cardiac contraindications, leucopenia, age, retinopathy, neoplasia). The others could either be 
improved (non-compliance, refusal to be treated, drug abuse), be transient (pregnancy) or be related to 
guidelines' criteria (normal ALT). The recent demonstration, indeed, that the therapy is as effective in patients 
with normal ALT as in patients with elevated transaminases [24] probably will increase the rate of eligible 
patients. 
 
Table 3: Comparison of European and US series versus the Belgian series 




et al. (France) [22] 
P Rowan et al. 
(US Veterans) 
[13] 
P Rocca et al. 
(US community) 
[17] 
P Falck-Ytter et al. 
(US academic) 
[15] 





n 299 1872  580  366  293  100  
Age (years) (mean ± SD) 43.1 ± 15.6 43 ± 4 NS 51 ±5 S 40.2 ± na na 50± na na 47.3 ± 5.6 S 
Ethnic origin            
Caucasians 274 (92%) 976/1059 (92%)  251 (43%)  277 (76%)  158 (54%)  49 (49%)  
Africans 22 (7%) 83/1059 (4%) NS 250 (43%) S 89 (24%) S 102 (35%) S 51 (51%) S 
Risk factor            
Transfusion 127 (43%) 655 (35%)  114/537 (21%)  89 (24%)  35 (1 2%)  13/74 (1 8%)  
Intravenous drug use 66 (22%) 599 (32%) S 343/537 (63%) S 156 (43%) S 1 93 (65%) S 55/74 (74%) S 
Genotype            
Genotype 1 89/134 (66%) 851  (46%)  na  na  na  na  
Non-genotype 1 45/134 (34%) 611  (54%) NS na  na  na  na  
Treatment            
Treated 123 na  174  55  83  32  
Untreated 1 76 (59%) na  406 (70%) S 1 79 (77%) S 210 (72%) S 68 (68%) NS 
S, significant difference with the Belgian series at the P<0.05 level; na, data not available. Patients in the US series were older and more 
likely to be African-Americans and intravenous drug users than those in the Belgian series. The proportion of untreated patients was higher 
in the US series. Belgian patients were, on the contrary, similar to French patients as far as age, ethnic origin or genotype distribution were 
concerned. 
 
The most frequent reason for the patient refusing therapy was the fear of potential adverse events. Neither the 
results of genotype determination nor of liver biopsy were predictive of acceptation of therapy in patients 
theoretically eligible for therapy (Table 2). The side-effect profile of peginterferon versus non-pegylated 
interferon being quite similar, it is not surprising that most patients who initially refused therapy maintained their 
position over the 7 years of this study despite the demonstration during these past years of an increased 
probability of sustained viral response afforded by peginterferon. The side effect profile of the current regimen 
of treatment of hepatitis C thus remains a serious barrier to therapy. 
The overall rate of sustained viral response (41%) observed in the treated patients from 1996 to 2003 was very 
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similar to that (40%) observed in academic hospitals from 1997 to 2001 in the United States [25]. The rate of 
discontinuation of treatment (16%) was also similar to those observed in registration trials of pegylated 
interferon and ribavirin [5,26]. This means that only 50 patients out of 299 referred for chronic hepatitis C (17%) 
became sustained responders, a figure very close to what has been reported in a teaching county hospital in the 
United States (13%) [15]. 
In real life, the majority of patients with chronic hepatitis C are not eligible for interferon plus ribavirin-based 
therapies. An important barrier to treatment remains the safety profile of these therapies. That emphasizes the 
need to continue to explore alternative treatment options or strategies for these patients. 
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